Heart rate variability as a measure of pain intensity in patients with cancer-related pain.

No registrations found.

Ethical review	Positive opinion
Status	Recruiting
Health condition type	-
Study type	Interventional

Summary

ID

NL-OMON20253

Source
NTR

Brief title
N/A

Health condition

Patients with malignancy visiting our outpatient clinic who have a pain intensity of at least 5 on a visual analogue scale (ranging from 0-10) can be included.

Sponsors and support

Primary sponsor: UMCG
Source(s) of monetary or material Support: UMCG

Intervention

Outcome measures

Primary outcome

Correlation between the pain intensity as measured by the visual analogue scale and as measured by heart rate variability.

Secondary outcome

1. Correlation between the response to pain medication using the visual analogue scale and the EORTC QLQ-C30 questionnairel;

2. correlation between the response to pain medication using heart rate variability measures and the EORTC QLQ-C30 questionnaire.

Study description

Background summary

N/A

Study objective

Heart rate variability measures correlate with pain intensity in patients with advanced cancer.

Study design

N/A

Intervention

Heart rate variability measurements will be performed on day 0 (before start of pain medication), day 2 and day 7.

Contacts

Public
A. Reyners
[default]
The Netherlands
Scientific
A. Reyners
[default]
The Netherlands

Eligibility criteria

Inclusion criteria

1. Patients with known metastatic malignancy;

2. Patients with a pain intensity of at least 5 on a visual analogue pain scale;

3. Patients able to have heart rate measures taken;

4. Patients able to fill in the EORTC QLQ-C30;

5. Patients should have sinus rhythm;

6. Performance score 0, 1 or 2;

7. Informed consent should be given.

Exclusion criteria

1. Patients with neuropathic pain;

2. Patients using medication that interferes with HRV;

3. Patients who have hemodynamically significant cardiac valvular abnormalities, severe chronic heart failure (NYHA III-IV), a history of vagotomy or sympathectomy;

4. Patients with other conditions / illnesses that can influence autonomic function;

5. Patients with brain metastases;

6. Patients who are treated with chemotherapy;

7. Patients who will start with chemotherapy and/or radiotherapy within the week of the study.

Study design

Design

Study type:	Interventional
Intervention model:	Other
Allocation:	Non-randomized controlled trial

Control: N/A , unknown

Recruitment

NL

Recruitment status:	Recruiting
Start date (anticipated):	01-05-2006
Enrollment:	30
Type:	Anticipated

Ethics review

Positive opinion

Date:	08-03-2006
Application type:	First submission

Study registrations

Followed up by the following (possibly more current) registration

No registrations found.

Other (possibly less up-to-date) registrations in this register

No registrations found.

In other registers

Register	ID
NTR-new	NL600
NTR-old	NTR656

Register	ID
Other	: N/A
ISRCTN	Incomplete info for ISRCTN

Study results

Summary results
N/A